Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth, NovioGendix Share $1.1M Grant for Bladder Cancer Research

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today announced it will be sharing a $1.1 million grant with NovioGendix to develop tumor markers for bladder cancer.

The grant comes from Eurotrans-Bio, a European Commission initiative to foster cross-border R&D between companies and academia in the biotechnology space.

MDxHealth and NovioGendix together will use the funds to discover and validate tumor markers that may be predictive of tumor progression into the muscle in developing invasive-stage bladder cancer. The partners will use DNA methylation technologies, DNA sequencing, and RNA expression profiles on clinical samples collected from bladder cancer patients from the urology department at Radboud University Nijmegen Medical Centre in the Netherlands.

NovioGendix is a molecular diagnostics firm spun out of RUNMC.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.